Skip to content Skip to footer
Top 20 Biopharma Deal Termination 2024

Top 20 Biopharma Deal Terminations of 2024

Shots: In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…

Read more

RNAi Therapeutic Top 20 2022

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

Shots:RNAi Therapeutic leverages the biological response of degrading (mRNA) before it gets translated into a protein. By using short double-stranded RNA in silencing a targeted disease-causing mutation, researchers are working steadfastly in multiple indications to expand RNAi therapeuticRNAi therapy comes to the rescue when targeting a specific protein gets difficult using a conventional…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]